Kid’s long-term safety follow-up for OLZ and SAM treatment
Part of Mental health clinical trials.
This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier related pediatric study recently (or stopped early due to a specific weight-gain rule)
- Your clinician believes you may benefit from continuing OLZ/SAM treatment
- You can take part as an outpatient (not staying in the hospital for study visits)
- There must be family support at home, and you must not be a safety risk to yourself or others
- A parent or legal guardian must reliably help with treatment, visit attendance, and study rules
- You must follow the study’s pregnancy prevention (contraception) requirements during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
This study tests a combination medicine (xanomeline and trospium chloride) to see if it is safe and tolerable over a longer period for children and adolescents with psychiatric disorders, especially those with autism-related irritability. It may help families understand if this treatment can be used beyond the initial study period.
This study is testing how safe and tolerable an investigational medication is over the long term (52 weeks) when added to your current antipsychotic treatment. It's for people with schizophrenia whose symptoms are stable, and it aims to see if the new medication can help without causing serious side effects.
This is an observational (non-intervention) study that follows adults with schizophrenia who are taking specific “atypical” antipsychotic medicines long-term. Researchers want to learn about patients’ experiences and outcomes while on these treatments.
This trial tests a new drug, ML-007C-MA, for adults with schizophrenia who may benefit from ongoing treatment. It aims to see how safe and effective the drug is over a longer period.
This trial tests a new medication called SEP-363856 over a long period for people with schizophrenia who are currently stable. It looks at how well the drug works and its safety over time.
Hear when a new Bipolar I Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.